North East and North Cumbria
ICS Formulary
ICS Formulary
5 Infections
05-01-07 Some other antibacterials
Links
MHRA Drug Safety Update (Dec 2014): Linezolid: restricted indication
Clinical Commissioning Policy: Inhaled Therapy for Adults and Children with Cystic Fibrosis- COVID-19 Therapeutic Alert
- Interim Clinical Commissioning Policy: Antivirals or neutralising monoclonal antibodies in the treatment of COVID-19 in hospitalised patients (Version 5 - effective from 10th February 2022)
- MHRA Drug Safety Update (Dec 2014): Linezolid: restricted indication
- MHRA Drug Safety Update (Dec 2014): Linezolid: restricted indication
- MHRA Drug Safety Update (Nov 2014): Colobreathe (colistimethate sodium dry powder for inhalation): risk of capsule breakage from inhaler device
- NENC Penicillin Allergy Assessment primary care for adult patients (February 2024)
- NICE CG64: Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures
- NICE NG110: Prostatitis (acute): antimicrobial prescribing
- NICE NG114: Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing
- NICE NG120: Cough (acute): antimicrobial prescribing
- NICE NG125: Surgical site infections: prevention and treatment
- NICE NG15: Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use
- NICE NG152: Leg ulcer infection: antimicrobial prescribing
- NICE NG153: Impetigo: antimicrobial prescribing
- NICE NG182: Insect bites and stings: antimicrobial prescribing
- NICE NG184: Human and animal bites: antimicrobial prescribing
- NICE NG190: Secondary bacterial infection of eczema and other common skin conditions: antimicrobial prescribing
- NICE NG195: Neonatal infection: antibiotics for prevention and treatment
- NICE NG199: Clostridioides difficile infection: antimicrobial prescribing
- NICE NG63: Antimicrobial stewardship: changing risk-related behaviours in the general population
- NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
- North of Tyne, Gateshead and North Cumbria - Antibiotic and Diagnostic quick reference tools
- Primary Care Antimicrobial Guidelines
- TA276:Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis
- TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy
- TEWV: Antibiotic Prescribing Procedure
- UK Interim Clinical Commissioning Police - Therapies for patients with symptomatic hospital-onset COVID-19